Research programme: anti-CD40L and anti-CD40 agents - Bristol-Myers Squibb
Alternative Names: Anti-5c8 - Bristol-Myers Squibb; Anti-CD40L antibody - BMS; Anti-gp39 - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody MR1; Anti-T-BAM - Bristol-Myers Squibb; Anti-TRAP - Bristol-Myers Squibb; BMS-202448; MR1Latest Information Update: 07 Mar 2025
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors; CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 07 Mar 2025 No development reported - Preclinical for Immunological disorders in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Immunological-disorders in USA
- 28 Sep 2024 No recent reports of development identified for phase-I development in Immunological-disorders in USA (Parenteral)